Lecture 11: Receptors
Role of Receptors in Pharmacology and Drug Discovery
By understanding signaling mechanisms, assays can be designed to study drugs at the cellular level during the discovery process.
Information regarding receptor structure and signaling is used to predict the consequences of mutations that give rise to specific diseases.
Knowing the detailed structure of different receptors allows for the design of molecules that selectively activate or inhibit them.
The ability to predict how activating or inhibiting a receptor will impact cell function is a primary goal of pharmacology.
Core Functions of Receptors
Receptors serve several essential functions in a biological system:
Recognize a specific stimulus.
Transfer the stimulus into the cell.
Amplify the cytoplasmic signal.
Modulate effector systems over time.
Adapt the system through feedback mechanisms.
In multicellular organisms, the selective expression of specific receptors and the molecules involved in signal transduction allows cells to respond specifically to particular stimuli.
Drugs that act through receptors exploit these natural functions to modulate the function of specific cells in the tissues where the receptors are expressed.
While the molecular nature of a receptor or signaling mechanism cannot be predicted solely from the stimulus, testable predictions can be made if the class/structure of the receptor and the signal transduction pathways are understood.
Type 1 Receptors: Ligand-Gated Ion Channels (LGICs)
Ligand-gated ion channels require a ligand to bind to the channel to induce a conformational change that leads to the opening of the pore.
The pore allows ions to flow down their concentration gradient.
Whether positive () or negative () ions pass through depends on the amino acids lining the pore of the channel.
The size of the channel also significantly impacts ion flow.
Detailed categories of Ligand-Gated Ion Channels include:
Acid-sensing (proton-gated) ion channels (ASICs).
receptors.
Epithelial sodium channel (ENaC).
receptors.
Ionotropic glutamate receptors.
Glycine receptors.
receptors.
Nicotinic acetylcholine receptors (nAChR).
receptors.
ZAC.
Other related ion channels include:
Voltage-gated ion channels (e.g., sodium, calcium, proton, and potassium channels).
Cyclic nucleotide-regulated channels.
Ryanodine receptors.
Transient Receptor Potential (TRP) channels.
Aquaporins.
Chloride channels.
Connexins and Pannexins.
Piezo channels.
Store-operated ion channels.
The Nicotinic Acetylcholine Receptor (nAChR) as a Model
The nicotinic ion channel is the most widely studied ligand-gated channel.
Structure and Mechanism:
It consists of subunits.
Two of these subunits have ligand-binding sites.
Binding of two ligands is required for the necessary conformational change to twist the aqueous pore open.
Pharmacological Target: Nicotine:
Nicotine acts at the nicotinic acetylcholine receptor.
This channel responds to both nicotine and acetylcholine.
nAChRs are expressed in the peripheral nervous system (neuromuscular junction), the sympathetic and parasympathetic nervous systems at pre-ganglionic neurons, and the central nervous system (CNS).
In the CNS, nicotine acts to release dopamine in the reward pathway, contributing to its addictive effect.
Subunit Diversity and Subtype Selectivity
Complexity in subunit combinations provides diversity and opportunities for targeted drug development.
Subunit composition impacts the pharmacology; variations in amino acids lead to slight variations in structure, meaning agonists and antagonists may show preference for one isoform of a receptor over another.
Selective Drug Opportunity:
The CNS receptor type is prevalent in reward pathways leading to nicotine addiction.
It is desirable to develop drugs that act as selective antagonists to the receptor without impacting peripheral nicotinic receptors.
Functional Consequences of Subunit Variation:
Muscle Version: Mainly permeable to sodium () and potassium (). Opening leads to influx, depolarization, and muscle excitation.
CNS Version: Highly selective toward calcium (Ca^{2+). Calcium acts as a second messenger, activating various proteins, leading to functional consequences distinct from simple depolarization.
Characteristic Profiles of Nicotinic Receptor Subtypes
Muscle Type (Adult Form):
Main Molecular Form: .
Location: Skeletal neuromuscular junction (mainly postsynaptic).
Response: Increased cation permeability (, ); Excitatory.
Agonists: Acetylcholine, Carbachol, Succinylcholine.
Antagonists: Tubocurarine, Pancuronium, Atracurium, Vecuronium, -Bungarotoxin.
Ganglion Type:
Main Molecular Form: .
Location: Autonomic ganglia (mainly postsynaptic).
Response: Increased cation permeability (, ); Excitatory.
Agonists: Acetylcholine, Carbachol, Nicotine, Epibatidine, Dimethylphenylpiperazinium.
Antagonists: Trimetaphan, Mecamylamine, Hexamethonium, -Conotoxin.
CNS Type 1 ( type):
Main Molecular Form: .
Location: Many brain regions; pre- and postsynaptic.
Response: Increased cation permeability (, ); Pre- and postsynaptic excitation.
Agonists: Nicotine, Epibatidine, Acetylcholine, Cytosine, Varenicline.
Antagonists: Mecamylamine, -Conotoxin.
CNS Type 2 ( type):
Main Molecular Form: .
Location: Many brain regions; pre- and postsynaptic.
Response: Increased cation permeability (, ); Pre- and postsynaptic excitation.
Agonists: Epibatidine, Dimethylphenylpiperazinium, Varenicline.
Antagonists: -Bungarotoxin, -Conotoxin, Methylaconitine.
Note: The receptor produces large entry, evoking transmitter release.
Type 2 Receptors: G-Protein Coupled Receptors (GPCRs)
GPCRs represent the largest family of receptors in the human genome, with over genes coding for proteins with this structure.
Structure: These possess a characteristic structure of transmembrane domains.
Orphan Receptors: Many GPCRs have been identified structurally but have no known natural ligand.
Classes of GPCRs:
Class A, B, and C (and others like Frizzled).
Classes are distinguished by structural features of the extracellular domains that define the ligand-binding site.
Ligand Specificity:
Muscarine was identified as an agonist that works on muscarinic acetylcholine receptors but not nicotinic receptors.
Acetylcholine works on both nicotinic and muscarinic receptors.
Signaling Examples:
GPCRs are involved in sensing the environment, chemical communication, and homeostatic mechanisms.
Canonical Signaling Molecules: Adenylyl Cyclase, cAMP, , DAG, PKA, PKC, , , , , , and Arrestin.
The Endocannabinoid System (ECS)
The ECS is a collection of receptors and molecules located throughout the body responsible for maintaining biochemical and physiological balance (homeostasis).
Cannabinoid Receptors:
Receptors: Most commonly found on nerve cells in the brain, spinal cord, and other organs.
Receptors: Found in reproductive organs, the immune system, and the peripheral nervous system.
Mechanism: Cannabinoids like CBD and THC influence homeostasis by interacting with these receptors. In neurotransmission, lipid precursors from the postsynaptic neuron release cannabinoids to bind to receptors on the presynaptic neuron.
Type 3 Receptors: Receptor Tyrosine Kinases (RTKs)
RTKs are utilized by growth factor receptors, immune mediators (cytokines like Jak receptors), and the insulin receptor.
Structure and Activation:
Usually possess a single transmembrane domain.
Requires dimerization (two receptors coming together) typically caused by agonist binding.
The kinase enzyme is a built-in part of the receptor.
Signaling Pathway (e.g., Growth Factor Receptor):
Agonist binding causes a conformational change and dimerization.
Tyrosine autophosphorylation: Tyrosine kinases cross-phosphorylate each other.
Binding of SH2-domain proteins (e.g., Grb2), creating binding sites for adaptor proteins.
Activation of Ras through GDP/GTP exchange.
Activation of a kinase cascade: Raf Mek MAP kinase.
Phosphorylation of various transcription factors in the nucleus.
Impact on gene transcription and protein synthesis.
Tyrosine Kinase-Linked Receptors (Cytokine Receptors)
Unlike RTKs, the kinase is not built-in but is brought in by an associated protein such as Janus Kinase (Jak).
Process:
Dimerization and conformational change.
Activation of Jak.
Phosphorylation of the receptor and Jak.
Binding and phosphorylation of SH2-domain protein (Stat).
Dimerization of Stat.
Translocation to the nucleus for gene transcription.
Type 4 Receptors: Nuclear Receptors (NRs)
Approximately of drugs target nuclear receptors.
Categories: Divided into Class I and Class II.
Pharmacokinetics and Metabolism:
Pregnane X Receptor (PXR) detects xenobiotics (foreign molecules) and induces drug-metabolizing enzymes.
Example: CYP3A, which metabolizes approximately of prescription drugs, is regulated this way.
Receptors and Disease states
Autoantibodies:
Myasthenia gravis.
Graves' disease (thyroid hypersecretion): characterized by high metabolic rate, increased skin temperature, nervousness, tremor, tachycardia, and bulging eyes.
Mutations in receptors or signal transduction proteins:
Ligand-gated ion channels: Associated with epilepsy.
GPCRs: Activating mutations can lead to endocrine disorders.
adrenoceptors: Mutations can reduce the efficacy of asthma drugs.
RTKs and Kinases: Associated with many types of cancers due to uncontrolled growth.
Nuclear Receptors: Associated with inflammation, cancer, diabetes, cardiovascular disease, obesity, and reproductive disorders.
Summary of Pharmaceutical Targets
Most drugs target proteins; small molecule drugs bind to specific sites within proteins to alter their function.
Common protein drug targets include receptors, ion channels, enzymes, and transporters.
Drugs binding directly to receptors are classified as agonists or antagonists.
Detailed knowledge of protein structure and cellular function is essential for drug discovery and understanding drug action.